Rhythm Pharmaceuticals, Inc. (FRA:1RV)
Germany · Delayed Price · Currency is EUR | Market Cap | 6.69B +14.3% |
| Revenue (ttm) | 210.00M +53.5% |
| Net Income | -184.01M |
| EPS | -2.73 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | 96.00 |
| Previous Close | 92.50 |
| Day's Range | 92.50 - 96.00 |
| 52-Week Range | 63.00 - 101.00 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 4, 2026 |
About Rhythm Pharmaceuticals
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases in the United States and internationally. The company’s lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, Bardet-Biedl and Alström syndrome, Prader-Willi syndrome, and hypothalamic obesity. It is in Phase 3 clinical trials for treating acquired hypothalamic... [Read more]
Financial Performance
In 2025, Rhythm Pharmaceuticals's revenue was $189.76 million, an increase of 45.83% compared to the previous year's $130.13 million. Losses were -$201.92 million, -23.68% less than in 2024.
Financial numbers in USD Financial StatementsNews
Rhythm Pharmaceuticals Announces MHLW Approval of IMCIVREE® (setmelanotide) for Patients with Acquired Hypothalamic Obesity (HO) in Japan
-- Approximately 5,000 to 8,000 patients estimated to be living with acquired HO in Japan -- -- Commercial launch in Japan expected by end of 2026, pending final pricing determination --
Rhythm Pharmaceuticals Announces Appointment of Manher (AJ) Joshi as Chief Medical Officer
BOSTON, Aug. 17, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rar...
Rhythm Pharmaceuticals Transcript: Canaccord Genuity's 46th Annual Growth Conference
IMCIVREE continues to expand globally, with strong AHO launch momentum and broad physician adoption. Pipeline advances include upcoming phase III trials for oral and injectable MC4R agonists and plans for a pivotal PWS study. Cash reserves support operations for two years.
Rhythm Pharmaceuticals price target raised to $155 from $141 at RBC Capital
RBC Capital raised the firm’s price target on Rhythm Pharmaceuticals (RYTM) to $155 from $141 and keeps an Outperform rating on the shares.
Rhythm Pharmaceuticals price target raised to $154 from $151 at Canaccord
Canaccord raised the firm’s price target on Rhythm Pharmaceuticals (RYTM) to $154 from $151 and keeps a Buy rating on the shares. The firm updated its model following Q2 results…
Rhythm Pharmaceuticals price target raised to $143 from $142 at Citi
Citi analyst Samantha Semenkow raised the firm’s price target on Rhythm Pharmaceuticals (RYTM) to $143 from $142 and keeps a Buy rating on the shares.
Rhythm Pharmaceuticals price target raised to $160 from $155 at Citizens
Citizens raised the firm’s price target on Rhythm Pharmaceuticals (RYTM) to $160 from $155 and keeps an Outperform rating on the shares. Imcivree sales beat expectations, with strong HO launch…
Rhythm Pharmaceuticals Announces Participation in Upcoming Investor Conferences
BOSTON, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rar...
Rhythm Pharma's obesity drug shows promise for brain tumor-related weight condition
Rhythm Pharmaceuticals said on Tuesday its experimental weekly injectable drug helped reduce body weight in patients with a rare form of obesity caused by damage to the brain, according to prelimina...
Rhythm Pharmaceuticals Earnings Call Transcript: Q2 2026
IMCIVREE's U.S. launch for acquired hypothalamic obesity drove strong Q2 sales growth, with robust early demand, broad prescriber engagement, and positive payer response. International expansion and next-generation MC4R agonist development are progressing, supporting long-term growth.
Rhythm Pharmaceuticals Earnings release: Q2 2026
Rhythm Pharmaceuticals released its Q2 2026 earnings on August 4, 2026, summarizing the period's financial results.
Rhythm Pharmaceuticals Slides: Q2 2026
Rhythm Pharmaceuticals has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 4, 2026.
Rhythm Pharmaceuticals Quarterly report: Q2 2026
Rhythm Pharmaceuticals has published its Q2 2026 quarterly earnings report on August 4, 2026.
Rhythm Pharmaceuticals’ RM-718 shows efficacy in Phase 2 obesity trial
Rhythm Pharmaceuticals (RYTM) announced preliminary results from the ongoing Phase 2 trial evaluating RM-718, Rhythm’s investigational once-weekly MC4R agonist, in patients with acquired hypothalamic ...
Rhythm Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Update
-- U.S. launch of IMCIVREE ® (setmelanotide) for acquired hypothalamic obesity (HO) starts strong with more than 400 patient start forms since FDA approval as of June 30, 2026 -- -- Second quarter 202...
Rhythm Pharmaceuticals Announces Preliminary Data from Phase 2 Trial that Showed RM-718 Demonstrated Positive Efficacy Signal in Acquired Hypothalamic Obesity
-- -11.6% mean reduction in BMI from baseline at Week 16 (n=7) -- -- BMI reductions consistent with setmelanotide and bivamelagon --
Rhythm Pharmaceuticals initiated with an Overweight at JPMorgan
JPMorgan analyst Priyanka Grover initiated coverage of Rhythm Pharmaceuticals (RYTM) with an Overweight rating and $145 price target The firm likes Rhythm’s opportunity to grow Imcivree from a rare ge...
Rhythm Pharmaceuticals to Report Second Quarter 2026 Financial Results on Tuesday, August 4, 2026
BOSTON, July 21, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rar...
Rhythm Pharmaceuticals Announces The New England Journal of Medicine Publication of Phase 3 TRANSCEND Trial Results in Acquired Hypothalamic Obesity
BOSTON, July 08, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rar...
Rhythm Pharmaceuticals price target raised to $141 from $137 at RBC Capital
RBC Capital raised the firm’s price target on Rhythm Pharmaceuticals (RYTM) to $141 from $137 and keeps an Outperform rating on the shares as part of a broader research note…
Rhythm Pharmaceuticals price target raised to $151 from $143 at Canaccord
Canaccord analyst Whitney Ijem raised the firm’s price target on Rhythm Pharmaceuticals (RYTM) to $151 from $143 and keeps a Buy rating on the shares. The firm updated its model…
Rhythm Pharmaceuticals Announces Multiple New Data Presentations from MC4R Agonists in Acquired Hypothalamic Obesity (HO), Bardet-Biedl Syndrome (BBS) and Prader-Willi Syndrome (PWS) at ENDO 2026
BOSTON, June 15, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rar...
Rhythm Pharmaceuticals price target raised to $155 from $144 at Wells Fargo
Wells Fargo raised the firm’s price target on Rhythm Pharmaceuticals (RYTM) to $155 from $144 and keeps an Overweight rating on the shares. IMCIVREE’s six-month Prader-Willi syndrome update further de...
Rhythm announces preliminary data from Phase 2 trial of setmelanotide
Rhythm Pharmaceuticals (RYTM) announced preliminary data from a Phase 2 trial evaluating setmelanotide in patients with Prader-Willi syndrome delivered during the Endocrine Society’s Annual Meeting in...
Rhythm Pharmaceuticals Transcript: Study result
Interim phase II results in severe Prader-Willi syndrome show setmelanotide led to consistent reductions in BMI, fat mass, hyperphagia, and anxiety, with notable behavioral and quality of life improvements. The drug was well-tolerated, and all patients remained in the trial at six months.